Date: 2011-01-31
Type of information: Grant
Company: Amsterdam Molecular Therapeutics (The Netherlands)
Investors: AIPGENE consortium The AIPGENE consortium is led by Fundación para la Investigatión Médica Aplicada (FIMA, Spain), and in addition to AMT, includes Clínica Universidad de Navarra (Spain), Stockholms Läns Landsting (Sweden), Deutsches Krebsforschungszentrum (Germany), Digna Biotech (Spain) and Servicio Madrileño de Salud (Spain).
Amount: € 1.1 Million
Funding type: EU consortium Grant
Planned used: The European Union (EU) has finalized a € 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria (AIP). From the grant, made under the EU’s FP7 program, AMT will receive € 1.1 million. The grant will cover approximately 75% of AMT’s overall development costs to bring this product forward to completion of a Phase I/II study in humans. AMT holds the commercialization rights to the AIP gene therapy (AMT-021).
Others:
Therapeutic area: Rare diseases - Genetic diseases
